R Eric Davis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1106089/publications.pdf

Version: 2024-02-01

28 papers	14,913 citations	331670 21 h-index	501196 28 g-index
30 all docs	30 docs citations	30 times ranked	15073 citing authors

#	Article	IF	Citations
1	Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica, 2022, 107, 690-701.	3.5	43
2	Detecting FÃ¶rster resonance energy transfer in living cells by conventional and spectral flow cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2022, 101, 818-834.	1.5	7
3	Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL. Leukemia, 2022, 36, 1261-1273.	7.2	12
4	miR-181a Promotes Multiple Protumorigenic Functions by Targeting TGFÎ²R3. Journal of Investigative Dermatology, 2022, 142, 1956-1965.e2.	0.7	4
5	Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nature Communications, 2022, 13, 2801.	12.8	25
6	Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma. Cell Metabolism, 2021, 33, 78-93.e7.	16.2	57
7	Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma. Science Translational Medicine, 2019, 11, .	12.4	51
8	Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. Science Translational Medicine, 2019, 11, .	12.4	69
9	Frontline antibiotic therapy for earlyâ€stage Helicobacter pylori â€negative gastric MALT lymphoma. American Journal of Hematology, 2019, 94, E150-E153.	4.1	7
10	BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment. Journal of Clinical Investigation, 2019, 129, 1878-1894.	8.2	51
11	Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metabolism, 2018, 27, 977-987.e4.	16.2	398
12	Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma. Blood, 2018, 131, 2138-2150.	1.4	77
13	HSP110 and MYD88: blame the chaperone. Blood, 2018, 132, 462-463.	1.4	1
14	The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma. Neoplasia, 2017, 19, 772-780.	5.3	22
15	C-reactive protein promotes bone destruction in human myeloma through the CD32â€“p38 MAPKâ€“Twist axis. Science Signaling, 2017, 10, .	3.6	28
16	Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. Blood, 2017, 130, 995-1006.	1.4	84
17	Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. Oncotarget, 2016, 7, 79722-79735.	1.8	133
18	Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. Blood, 2016, 128, 1260-1269.	1.4	104

#	Article	IF	Citations
19	Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma. Science Translational Medicine, 2016, 8, 353ra113.	12.4	53
20	Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncology, The, 2014, 15, 69-77.	10.7	518
21	p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression. Nature Communications, 2014, 5, 4229.	12.8	49
22	Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment. Blood, 2013, 122, 357-366.	1.4	77
23	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature, 2010, 463, 88-92.	27.8	1,402
24	Effect of Long-term Storage in TRIzol on Microarray-Based Gene Expression Profiling. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2445-2452.	2.5	45
25	Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma. Science, 2008, 319, 1676-1679.	12.6	784
26	Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13520-13525.	7.1	868
27	Constitutive Nuclear Factor ÎºB Activity Is Required for Survival of Activated B Cellâ€“like Diffuse Large B Cell Lymphoma Cells. Journal of Experimental Medicine, 2001, 194, 1861-1874.	8.5	963
28	Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 2000, 403, 503-511.	27.8	8,977